Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07601607
What this trial is testing

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Sun Yat-sen University 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT05222555
What this trial is testing

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Who this might be right for
Diffuse Large B Cell Lymphoma
Incyte Corporation 53
Not applicableStudy completedNCT04150328
What this trial is testing

Lenalidomide Monotherapy in R/R DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
MorphoSys AG 490
Early research (Phase 1)UnknownNCT05039658
What this trial is testing

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Who this might be right for
DLBCL
Innovent Biologics (Suzhou) Co. Ltd. 50
Early research (Phase 1)Study completedNCT03467373
What this trial is testing

Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Who this might be right for
B-Cell LymphomaNon-Hodgkin Lymphoma
Hoffmann-La Roche 111
Early research (Phase 1)Study completedNCT02219737
What this trial is testing

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
CD20 PositiveRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 26
Not applicableNo Longer AvailableNCT04705454
What this trial is testing

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
ADC Therapeutics S.A.
Testing effectiveness (Phase 2)Study completedNCT03259529
What this trial is testing

Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
St. Petersburg State Pavlov Medical University 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04442022
What this trial is testing

Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc 501
Early research (Phase 1)Active Not RecruitingNCT04526834
What this trial is testing

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell Lymphoma+2 more
Tessa Therapeutics 21
Large-scale testing (Phase 3)Study completedNCT04833114
What this trial is testing

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
GWT-TUD GmbH 306
Early research (Phase 1)Ended earlyNCT03571828
What this trial is testing

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma(DLBCL)Mantle Cell Lymphoma (MCL)Follicular Lymphoma (FL)
Amgen 10
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Testing effectiveness (Phase 2)Looking for participantsNCT03356054
What this trial is testing

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Who this might be right for
DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland 37
Testing effectiveness (Phase 2)UnknownNCT04502394
What this trial is testing

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Who this might be right for
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Kartos Therapeutics, Inc. 84
Testing effectiveness (Phase 2)Study completedNCT01562990
What this trial is testing

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Who this might be right for
Diffuse Large B-Cell Lymphoma
The Lymphoma Academic Research Organisation 11
Early research (Phase 1)Not Yet RecruitingNCT07570017
What this trial is testing

Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
DLBCL
Guangzhou Lupeng Pharmaceutical Company LTD. 42
Early research (Phase 1)Looking for participantsNCT05512390
What this trial is testing

Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Diffuse Large B-Cell LymphomaChronic Lymphocytic LeukemiaFollicular Lymphoma
AbbVie 154
Testing effectiveness (Phase 2)Looking for participantsNCT06806033
What this trial is testing

Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05253118
What this trial is testing

Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Who this might be right for
DLBCL
Seoul National University Hospital 28
Load More Results